RxDoctor Payments Data

Jason Brown, MD

Family Medicine · Augusta, MENPI 1740592658

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $389 and has fallen 89.0% since, to $43 in 2025. Among family medicine clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$888in general payments, 2019–2025

Across 29 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$183
  • Pfizer$183
  • Amgen$133
  • Novo Nordisk$96
  • Sanofi Pasteur Inc.$76
  • Abbott$47
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$888 in reported general payments places this provider in the 90th percentile of 466 family medicine providers in Maine.

See all family medicine providers in Maine

Medicare billing

Part B allowed, 2024
$13,210
Medicare patients
88
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$57,164
EliquisApixaban24$25,654
TrulicityDulaglutide16$17,539
FarxigaDapagliflozin Propanediol19$17,322
EntrestoSacubitril/Valsartan13$8,643
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,009
Rosuvastatin Calcium37$1,081
Atorvastatin Calcium109$852
Pantoprazole Sodium85$838
Tamsulosin Hcl29$713
Albuterol Sulfate HfaAlbuterol Sulfate26$677
Omeprazole42$642
Metoprolol Succinate34$625
Losartan Potassium61$465
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$183$25,65424 claims
Lilly USA, LLCTrulicity$15$17,53916 claims
AstraZenecaFarxiga$33$17,32219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 466 family medicine providers in Maine.

Other family medicine in Augusta

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →